Amyotrophic Lateral Sclerosis, Glutamate, and Oxidative Stress
Andreas Plaitakis and P. Shashidharan
Mount Sinai School of Medicine
One Gustave L. Levy Place
New York, NY 10029
phone: 212-241-7310
REFERENCES
1. Allaoua H, Chaudieu I, Krieger C, et al. Alterations
in spinal cord excitatory amino acid receptors in amyotrophic lateral sclerosis.
Brain Res 1992;579:169–172.
2. Aoki, M., Lin, C. L., Rothstein, J. D., Geller, B. A., Hosler,
B. A., Munsat, T. L., Horvitz, H. R. and Brown, R., Jr. Mutations in the glutamate
transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic
lateral sclerosis. Ann Neurol.1998;43: 645-653
3. Arriza, J. L., Fairman, W. A., Wadiche, J. I., Murdoch, G.
H., Kavanaugh, M. P. and Amara, S. G. (1994). Functional comparisons of three
glutamate transporter subtypes cloned from human motor cortex. J Neurosci. 1994;
14:5559-5569.
4. Arriza, J. L., Eliasof, S., Kavanaugh, M. P. and Amara, S.
G. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled
to a chloride conductance. Proc Natl Acad Sci U S A.1997; 94: 4155-4160
5. Babu GN, Bawari M, Mathur VN, Kalita J, Mistra UK. Blood glutamate
levels in patients with motor neuron disease. Clin Chim Acta 1998; 273:195-200
6. Battaglioli G, Martin DL, Plummer J, Messer A. Synaptosomal
glutamate uptake declines progressively in the spinal cord of a mutant mouse
with motor neuron disease. J Neurochem 1993;60: 1567–1569.
7. Blin O, Desnuelle C, Guelton C, et al. Clinique des
maladies du systeme nerveux et de l'appareil locomoteur. Rev Neurol 1991;147:292–294.
8. Block, W., Karitzky, J., Traber, F., Pohl, C., Keller,
E., Mundegar, R. R., Lamerichs, R., Rink, H., Ries, F., Schild, H. H. and Jerusalem,
F. Proton magnetic resonance spectroscopy of the primary motor cortex in patients
with motor neuron disease: subgroup analysis and follow-up measurements. Arch
Neurol. 1998; 55: 931-936.
9. Bristol, L. A. and Rothstein, J. D. Glutamate
transporter gene expression in
amyotrophic lateral sclerosis
motor cortex. Ann Neurol.1996; 39: 676-679.
10. Browne, S. E., Bowling, A. C., Baik, M. J.,
Gurney, M., Brown, R., Jr. and Beal, M. F. (1998). Metabolic dysfunction in
familial, but not sporadic, amyotrophic lateral sclerosis. J Neurochem.71, 281-287
11.
Bruijn,
L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama,
E., Reaume, A. G., Scott, R. W. and Cleveland, D. W. (1998). Aggregation and
motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type
SOD1. Science.281, 1851-1854
12. Budai D, Wilcox GL, Larsen AA. Enhancement of NMDA-evoked
neuronal activity by glycine in the rat spinal cord in vivo. Neurosci Lett
1992;135:265–268.
13. Canton T, Pratt J, Stutzmann
JM, Imperato A, Boireau A. Glutamate uptake is decreased tardively in the spinal
cord of FALS mice. Neuroreport 1998;3:775-8).
14. Clements JD., Lester RAJ,
Tong CE and Jahr CE. The time course of glutamate in the synaptic cleft. Science
1992;258:1498-1501
15.
Crow,
J. P., Sampson, J. B., Zhuang, Y., Thompson, J. A. and Beckman, J. S. (1997).
Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide
dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite.
J Neurochem.69, 1936-1944
16.Constantakakis E, Plaitakis A. N-acetyl-aspartate
and N-acetyl-aspartyl-glutamate are altered in amyotrophic lateral sclerosis.
Ann Neurol 1988;24:478.
17. Curtis DR, Watkins JC. The excitation and depression
of spinal neurons by structurally related amino acids. J Neurochem 1960;
6:117–141.
18. Dalakas MC, Harazawa J, Brooks RA, et al. Lowered cerebral
glucose utilization in amyotrophic lateral sclerosis. Ann Neurol 1987;22:580–586.
19.
Durham,
H. D., Roy, J., Dong, L. and Figlewicz, D. A. (1997). Aggregation of mutant
Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol
Exp Neurol.56, 523-530
20. Fairman, W. A., Vandenberg, R. J., Arriza, J. L., Kavanaugh,
M. P. and Amara, S. G. An excitatory amino-acid transporter with properties
of a ligand-gated chloride channel. Nature. 1995; 375; 599-603.
21. Fonnum F. Glutamate: a neurotransmitter in mammalian
brain. J Neurochemistry,
1984;42:1–11.
22. Fray, A. E., Ince, P. G., Banner, S. J., Milton, I. D.,
Usher, P. A., Cookson, M. R. and Shaw, P. J. (1998). The expression of the glial
glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical
study. Suppl Eur J Neurosci. 1998; 10: 2481-2489.
23. Futura A, Martin LI, Lin CL, Dykes-Hoberg M,
Rothstein JD. Cellular and synaptic localization of the neuronal glutamate transporters
excitatory amino acid transporter 3 and 4. Neuroscience 1997;81:1031-1042.
24. Gegelashvili, G., Danbolt, N. C. and Schousboe, A. Neuronal
soluble factors differentially regulate the expression of the GLT1 and GLAST
glutamate transporters in cultured astroglia. J Neurochem. 1997; 69:
2612-2615
25. Gredal O, Pakkenberg B, Nielsen M. Muscarinic,
N-methyl-D-aspartate (NMDA) and benzodiazepine receptor binding sites in cortical
membranes from amyotrophic lateral sclerosis. J Neurol Sci. 1996; 143:121-125.
26. Ghadge, G. D., Lee, J. P., Bindokas, V. P., Jordan,
J., Ma, L., Miller, R. J. Roos, R. P.
(1997). Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis:
molecular mechanisms of neuronal death and protection. J Neurosci.1997; 17:
8756-8766.
27. Hall, E. D., Andrus, P. K., Oostveen, J. A.,
Fleck, T. J. and Gurney, M. E. (1998). Relationship of oxygen radical-induced
lipid peroxidative damage to disease onset and progression in a transgenic model
of familial ALS. J Neurosci Res.1998; 53: 66-77.
28. Ikonomidou C, Qin Qin Y, Labruyere J,
Olney JW. Motor neuron degeneration
induced by excitotoxin agonists has features in common with those seen in SOD-1
transgenic mouse model of amyotrophic lateral sclerosis. J. Neuropathol Exp
Neurol 1996;55:211-24.
29. Iwasaki Y, Ikeda K, Kinoshita M. Plasma amino acid levels
in patients with amyotrophic lateral sclerosis. J Neurol Sci 1992;
107:219–222
30. Kanai Y, Hediger MA. Primary structure and functional
characterization of a high-affinity glutamate transporter. Nature 1992;
360:467–471.
31. Langlais PJ, Mair RG. Protective effects of the glutamate
antagonist MK-801 on pyrithiamine-induced lesions and amino acid changes in
brain. J Neurosci 1990;10:1664–1667.
32. Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J and
Danbolt NC. Differential expression of two glial glutamate transporters in rat
brain: quantitative and immunocytochemical observations. J Neurosci 1995; 15:1835-53
33. Levy LM, Lehre KP, Walaas I, Storm-Mathisen J,
Danbolt NC. Downregulation of glial glutamate transporters after glutamatergic denervation
in the rat brain. Eur J Neurosci 1995; 7:2036-41
34.
Lin,
C. L., Bristol, L. A., Jin, L., Dykes-Hoberg, M., Crawford, T., Clawson, L.
and Rothstein, J. D. Aberrant RNA processing in a neurodegenerative disease:
the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral
sclerosis. Neuron 1998; 20: 589-602.
35. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate
on the inner layer of the retina. AMA Arch Ophthalmol 1957;58:193–204.
36. Malessa S, Leigh PN, Bertel O, Sluga E, Hornykiewicz
O. Amyotrophic lateral sclerosis, glutamate dehydrogenase and transmitter amino
acids in the spinal cord. J Neurol Neurosurg Psychiatry 1991;54:984–988.
37. Mayer ML, Ladislav V Jr, Clements J. Regulation of NMDA
receptor desensitization in mouse hippocampal neurons by glycine. Nature
1989;338:425–427.
38. McNamara J, Fridovich I. Did radicals strike Lou Gehrig?
Nature 1993;362:20–21.
39. Medina
L, Figueredo-Cardenas G, Rothstein JD, Reiner A. Differential abundance of glutamate
transporter subtypes in amyotrophic lateral sclerosis (ALS)-vulnerable versus
ALS-resistant brain stem motor cell groups. Exp Neurol 1996; 14:287-95
40. Milton ID, Banner SJ, Ince PG, Piggott NH, Fray AE, Thatcher
N, Horne CH, Shaw PJ. Expression of the glial glutamate transporter EAAT2 in
human CNS: an immunocytochemical study. Brain Res Mol Brain Res. 1977;
52:17-31
41. Mitchell
JJ, Anderson KJ. Quantative autoradiographic analysis of excitatory amino acid receptors receptors in
the cat spinal cord. Neurosci Lett 1991; 124:269-272
42. Morrison BM, Janssen WG, Gordon
WJ, Morrison JH. Light and electron microscopic distribution of the AMPA receptor
subunit, GluR2, in the spinal cord of control and G86R mutant superoxide dismut ase transgenic mice . J Comp Neurol 1998; 395:523-34.
43. Mourelatos Z, Yachnis A, Rorke L, et al. The Golgi apparatus
of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 1993;33:608–615.
44. Murphy TH, Miyamoto M, Sastre A, et al. Glutamate toxicity
in neuronal cell line involves inhibition of cystine transport leading to oxidative
stress. Neuron 1989;2:1547–1558.
45. Nag S, Riopelle RJ. Spinal neuronal pathology
associated with continuous intrathecal infusion of N-methyl-D-aspartate
in the rat. Acta Neuropathol 1990;81:7–13.
46. Nagai, M., Abe, K., Okamoto, K. and Itoyama,
Y. Identification of alternative splicing forms of GLT-1 mRNA in the spinal
cord of amyotrophic lateral sclerosis patients. Neurosci Lett.1008; 244:165-168.
47. Nakanishi S. Molecular diversity of glutamate receptors
and implications for brain function. Science 1992;258:597–603.
48. Nicklas WJ, Krespan B, Berl S. Effect of
kainate on ATP levels and glutamate metabolism in cerebellar slices. Eur
J Pharmacol 62:209–215.
49. O'Brien RJ, Fischbach GD. Modulation of embryonic
chick motoneuron glutamate sensitivity
by interneurons and agonists. J Neurosci 1986;6:3290–3296.
50. Olney JW, Ho OL, Rhee V. Cytotoxic effects of acidic
and sulfur containing amino acids on the infant mouse central nervous system.
Exp Brain Res 1971;14:61–76.
51.Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in
mammalian central nervous system. Prog Neurobiol 1998; 54:581-618.
52. Perl TM, Bedard L, Kosatsky T, et al. An outbreak of
toxic encephalopathy caused by eating mussels contaminated with domoic acid.
N Engl J Med 1990;322:1775–17780.
53. Perry TL, Hansen S, Jones K. Brain glutamate deficiency
in amyotrophic lateral sclerosis. Neurology 1987;37:1845–1848.
54. Perry TL, Krieger C, Hansen S, Eisen A. Amyotrophic lateral
sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol
1990;28:12–17.
55. Perry TL, Hansen S. What excitotoxin kills
striatal neurons in Huntington's disease? Clues from biochemical studies. Neurology
1990;40:20–24.
56. Pioro
EP, Preul MC, Antel JP, Arnold DL. 1M-magnetic resonance spectroscopy
demonstrates decreased N-acetyl-aspartate in the cerebrum of patients
with amyotrophic lateral sclerosis. Neurology 1993;44(Suppl 2):405P.
57. Pioro, E. P. MR spectroscopy in amyotrophic lateral sclerosis/motor
neuron disease. J Neurol Sci.1997; 152: S49-53.
58. Pines G, Danbolt NC, Bjoras M, et al. Cloning and expression
of a rat brain L-glutamate transporter. Nature 1992;360:464–467.
59. Plaitakis A, Nicklas WJ, Berl S. Alterations in uptake
and metabolism of aspartate and glutamate in brain of thiamine deficient animals.
Brain Res 1979;171:489–502.
60. Plaitakis A, Berl S, Yahr MD. Abnormal glutamate
metabolism in an adult-onset degenerative neurological disorder. Science
1982; 216:193–196.
61. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism
in amyotrophic lateral sclerosis. Ann Neurol 1987;22:575–5759.
62. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic
amino acids glutamate and aspartate are altered in the spinal cord and brain
in amyotrophic lateral sclerosis. Ann Neurol 1988;24:446–449.
63. Plaitakis A. Glutamate dysfunction and selective motor
neuron degeneration in amyotrophic lateral sclerosis. A hypothesis. Ann Neurol
1990;28:3–8.
64. Plaitakis A, Mandeli J, Fesdjian CO, Smith J, Sivak M.
Dysregulation of glutamate metabolism in ALS: correlation with gender and disease
type. Neurology 1990;41(Suppl 1):392–393.
65. Plaitakis A, Constantakakis E. Altered metabolism
of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate
in amyotrophic lateral sclerosis. Brain Res Bull 1993;30:381–386.
66. Plaitakis A, Shashidharan
P. Amyotrophic lateral sclerosis, glutamate and oxidative stress. Psychopharmacology.
In Bloom FE, Kupfer DJ, edts. The Fourth Generation of Progress 1995
pp 1531-43.
67. Regan RF, Choi DW. Glutamate neurotoxicity
in spinal cord cell culture. Neuroscience
1991;43:585–591.
68. Rosen DR, Siddique T, Patterson D, et al.
Mutations in CU/Zn superoxide dismutase gene are associated with familial amyotrophic
lateral sclerosis. Nature 1993;362:59–62.
69. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal
excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol
1990;28:18–25.
70. Rothstein
JD, Kuncl R, Chaudhry V, et al. Excitatory amino acids in amyotrophic lateral
sclerosis: an update. Ann Neurol 1991;30:224–225.
71. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate
transport by the brain and spinal cord in amyotrophic lateral sclerosis. N
Engl J Med 1992;326:1464–1468.
72. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic
inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc
Natl Acad Sci USA 1993;90:6591–6595.
73. Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin,
L. J. and Kuncl, R. W. (1995). Selective loss of glial glutamate transporter
GLT-1 in amyotrophic lateral sclerosis. Ann Neurol.1995; 38: 73-84.
74. Samarasinghe S, Virgo L, de Belleroche J. Distribution
of N-methyl-D-aspartate glutamate receptor subunit NR2 in control and amyotrophic
lateral sclerosis spinal cord. Brain Res 1996; 727:233-237.
75. Shashidharan P, Plaitakis A. Cloning and characterization
of a glutamate transporter cDNA from human cerebellum. Biochim Biophys Acta
1993;1216:161–164.
76. Shashidharan, P., Huntley, G. W., Meyer, T., Morrison,
J. H. and Plaitakis, A. Neuron-specific human glutamate transporter: molecular
cloning, characterization and expression in human brain. Brain Res.1994; 662:
245-250.
77. Shashidharan, P., Wittenberg, I. and Plaitakis, A. Molecular
cloning of human brain glutamate/aspartate transporter II. Biochim Biophys Acta
1994.1191: 393-396.
78. Shashidharan P, Huntley GW, Murray J, Walsh MJ, Buku
A, Moran T, Morrison JH and Plaitakis A. Immunohistochemical Localization of
Neuron-specific Glutamate Transporter (EAAC1) in rat brain and spinal cord revealed
by a novel Monoclonal Antibody Brain Res. 1997; 773:139-148.
79. Shaw PJ, Chinnery RM, Ince
PG. [3H]D-aspartate binding sites in the normal spinal cord and changes in motor
neuron disease: a quantitative autoradiographic study. Brain Res 1994; 665:195-201
80. Shaw PJ, Ince PG, Mathews JN, Johnson M and Candy JM.
N-methyl-D-aspartate (NMDA) receptors in the spinal cord and motor cortex in
motor neuron disease: a quantitative autoradiographic study using [3H]MK-801.
Brain Res 1994:637:297-302.
81. Shaw PJ, Forrset V, Ince PG, Richardson JP and Wastell
HJ. CSF and plasma amino acid levels in motor neuror disease: elevation of CSF
glutamate in a subset of patients. Neurodegeneration 1995; 4:209-216.
82. Shaw, P. J., Ince, P. G., Falkous, G. and Mantle, D.
Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann
Neurol.1995; 38: 691-695
83. Sies H, ed. Oxidative stress London: Academic
Press, 1985;273–303.
84. Storck T, Shulte S, Hofmann K, Stoffel W. Structure,
expression, and functional analysis of a Na+-dependent glutamate/aspartate
transporter from rat brain. Proc Natl Acad Sci USA 1992;89:10955–10959.
85. Tanaka, K., Watase, K., Manabe, T., Yamada, K., Watanabe,
M., Takahashi, K., Iwama, H., Nishikawa, T., Ichihara, N., Kikuchi, T., Okuyama,
S., Kawashima, N., Hori, S., Takimoto, M. and Wada, K.. Epilepsy and exacerbation
of brain injury in mice lacking the glutamate transporter GLT-1. Science.1997;
276: 1699-1702
86. Thomson AM, Walker VE, Flynn DM. Glycine enhances NMDA-receptor
mediated synaptic potentials in neocortical slices. Nature 1989;338:422–424.
87. Tsai GC, Stauch-Sluser B, Sim L, et al. Reductions in
acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral
sclerosis. Brain Res 1991;556:151–156.
88. Virgo L, de Belleroche J.
Induction of the immediate early gene c-jun in human spinal cord in amyotrophic
lateral sclerosis with concomitant loss of NMDA receptor NR-1 and glycine transporter
mRNA. Brain Res 1995; 676:196-204
89. Waelsch H, Berl S, Rossi CA, Clarke DD, Purpura DP. Quantitative
aspects of CO2 fixation in mammalian brain in vivo. J Neurochem,
1964;11:717–728.
90. Wiedemann, F. R., Winkler, K., Kuznetsov, A. V., Bartels,
C., Vielhaber, S., Feistner, H. and Kunz, W. S. Impairment of mitochondrial
function in skeletal muscle of patients with amyotrophic lateral sclerosis.
J Neurol Sci.1998; 156: 65-72.
published 2000